Tempest Therapeutics' (TPST) "Neutral" Rating Reiterated at HC Wainwright

Tempest Therapeutics (NASDAQ:TPST - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. They currently have a $16.00 target price on the stock. HC Wainwright's price target would suggest a potential upside of 119.18% from the stock's previous close.

Separately, Scotiabank reiterated a "sector perform" rating and issued a $9.00 target price (up previously from $7.00) on shares of Tempest Therapeutics in a research note on Thursday, April 10th.

Tempest Therapeutics Price Performance

Shares of TPST stock traded up $0.34 on Thursday, hitting $7.30. The company's stock had a trading volume of 33,949 shares, compared to its average volume of 156,424. The stock has a market capitalization of $25.69 million, a price-to-earnings ratio of -4.77 and a beta of -2.34. Tempest Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $49.27. The firm's fifty day moving average price is $10.13 and its 200-day moving average price is $11.79.

Tempest Therapeutics (NASDAQ:TPST - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($4.03) EPS for the quarter, missing analysts' consensus estimates of ($3.12) by ($0.91). The firm had revenue of $0.49 million during the quarter. Analysts predict that Tempest Therapeutics will post -1.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempest Therapeutics

Several large investors have recently modified their holdings of TPST. XTX Topco Ltd bought a new stake in Tempest Therapeutics in the third quarter valued at $34,000. Virtu Financial LLC acquired a new stake in shares of Tempest Therapeutics during the fourth quarter worth $36,000. Northern Trust Corp increased its holdings in Tempest Therapeutics by 233.2% in the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company's stock valued at $57,000 after purchasing an additional 47,461 shares during the last quarter. Millennium Management LLC bought a new position in Tempest Therapeutics during the fourth quarter worth about $158,000. Finally, Geode Capital Management LLC raised its position in shares of Tempest Therapeutics by 42.7% in the 3rd quarter. Geode Capital Management LLC now owns 220,067 shares of the company's stock valued at $308,000 after acquiring an additional 65,826 shares during the period. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.